The aim of this study is to review the clinical and economic rationale for the reimbursement of orlistat in responding obese patients with type 2 diabetes. METHODS: Data from seven randomized controlled clinical trials of orlistat in overweight and obese patients with type 2 diabetes were pooled. A subgroup analysis involving patients who achieved a response (defined as a weight loss of Z5% after 12 weeks of treatment) was conducted. The outcomes of the pooled analysis were then used to construct a Markov health economic model covering an 11-y period. The incidences of diabetes-related micro-and macrovascular complications were derived from the United Kingdom Prospective Diabetes Study. The effects of changes in body mass index, and the impact of micro-and macrovascular complications on utilities were derived from published sources. Publicly available cost data were used and are presented here in 2001 Euros. Discounting of 3% was applied. A probabilistic sensitivity analysis was conducted to examine the robustness of results. RESULTS: A total of 1249 patients treated with orlistat and 1230 given placebo were eligible for the intent-to-treat analysis. At the end of the study period, 23% of orlistat patients achieved a weight reduction of Z5%. These patients showed a mean decrease in HbA1C of 1.16%, a weight reduction of 8.6 kg, a reduction in total cholesterol of 5.3% and a reduction in systolic blood pressure of 5.2 mmHg. The base-case economic analysis revealed costs per quality-adjusted life year gained of h14 000 in Sweden and h13 600 in Switzerland. CONCLUSION: The data presented here support the utilization and reimbursement of orlistat in overweight and obese diabetic patients who respond to the treatment.
Introduction
In line with the global trends, the prevalence of obesity in Switzerland and Sweden is increasing at an alarming rate. [1] [2] [3] The threat of diabetes, the most well-known consequence of obesity, is particularly alarming, 4 as its chronic course and potentially severe complications have major implications for individual patients and for society. The total annual direct medical costs for the Swedish diabetes type 2 population were estimated to account for about 6% of the total national health care expenditure. 5 In Switzerland, mean annual type 2 diabetes-related medical costs per patient amounted to h2323 per year. They were particularly high in patients receiving insulin treatment or with complications. 6 The benefits of prevention are clear against that background. Weight loss and glycemic control are two key mechanisms in the primary and secondary prevention of type 2 diabetes. Some researchers estimate that up to two out of every three cases of type 2 diabetes are attributable to obesity. 7 Recommending weight loss has therefore become a standard of care for improving blood glucose control. 8 Orlistat, a potent inhibitor of pancreatic lipases, is one of few pharmacologic treatment options available to help patients with type 2 diabetes reduce body weight and gain better glycemic control. 9 A number of recent trials have clearly shown its beneficial effects on both weight and blood glucose. [10] [11] [12] [13] Based on that evidence, reports aimed at achieving reimbursement of orlistat were filed in Sweden and Switzerland. The licensing of orlistat in the European Union stipulates that treatment should be focused on those patients who respond by losing Z5% of their initial body weight within the first 12 weeks of treatment. However, termination of treatment in nonresponding patients (ie those who lose o5% of initial body weight within the first 12 weeks after randomization) was not considered in the above investigations. Therefore, a pooled meta-analysis of the clinical trials was conducted, focusing on the subgroup of patients who met the response criteria. In addition, a health economic model was designed. The aim of this publication is to review the clinical and economic rationale for reimbursement of orlistat used in the treatment of responding obese patients with type 2 diabetes.
Methods
European indication for orlistat and definition of response The therapeutic indication for orlistat in Europe includes a statement that treatment should be discontinued after 12 weeks if patients have been unable to lose at least 5% of their initial body weight (http://www.emea.eu.int). Based on this definition of response, a meta-analysis of published clinical trials of orlistat in type 2 diabetic patients was conducted. A cost-effectiveness model taking account of the findings of the meta-analysis was developed and applied to the Swiss and Swedish environments.
Meta-analysis of clinical data in responding type 2 diabetes patients Seven trials have investigated the use of orlistat in overweight and obese patients with type 2 diabetes. Three were conducted in North America: two in the US alone 11, 13 and one in the US and Canada. 12 The other four trials were conducted in Germany, 14 Spain, 15 Thailand 16 and South Africa. 17 The treatment duration was 1 y in four trials, [11] [12] [13] [14] and 6 months in the other three. In all protocols, patients were randomized to treatment with orlistat 120 mg or placebo t.i.d. plus a mildly reduced-calorie diet (500-600 kcal/day deficit). Four trials specified the antidiabetic medication used: sulfonylureas; 13,14 insulin; 11 and metformin. 12 Inclusion criteria for the remaining three trials included administration of a primary oral antidiabetic medication, but did not specify a particular drug class. The dose of antidiabetic agent was required to be stable in the 3 months prior to inclusion, but was allowed to vary during the course of the studies in order to maintain adequate blood glucose control. All patients also received ongoing instruction and support concerning diet and exercise. The seven studies were conducted according to the principles of the Declaration of Helsinki and were approved by the institutional review boards of the respective sites. Data from the seven multicenter, randomized, placebocontrolled trials were pooled, and a subgroup analysis was conducted based on the response criterion of at least 5% weight loss after 12 weeks. Intent-to-treat (ITT) analyses were performed on a last observation carried forward data set, and analysis of covariance was used to analyze the difference between treatment groups. Selected outcomes for the pooled analysis included the primary (ie weight loss and glycemic control) and secondary (ie blood pressure, lipid profile) end points of the clinical trials.
Cost-effectiveness analysis
As, generally speaking, clinical trials have a limited duration, a core element of most health economic analyses is the modelling of clinical outcome and the related economic costs beyond the clinical trial duration. In disease areas that apply surrogate parameters (eg HbA1C) as primary clinical trial end points, the projection beyond clinical trial duration involves two steps: (i) the development of the surrogate parameter has to be modelled over time (ie predict how the surrogate parameter in each of the treatment groups will evolve when the trial is complete) and (ii) linking the surrogate parameter to clinically and economically relevant disease-specific end points. Typical end points in diabetes include stroke and myocardial infarction. In order to model the occurrence of those events, the time is divided into intervals (eg years), also called cycles. 18 A patient transitions from cycle to cycle during which he or she can change health status, for example, increased/ decreased HbA1C, or experience a diabetes-related complication. During the next cycle, the same patient will have a different chance of experiencing a health event, such as a complication, depending on events in the prior previous cycle.
In order to project the change of the surrogate parameters as well as the related health states over time, health economists have to rely on outcomes studies conducted in the respective disease area. For the purpose of our model, we relied on the findings of the United Kingdom Prospective Diabetes Study (UKPDS 19 ), the most comprehensive outcomes study available in diabetes. In that study, HbA1C levels in 4585 patients are monitored over a time interval of 10 y and correlated to the hard diabetes-related end points such as stroke or myocardial infarction. Ratios for each of those complications are developed indicating the increase of relative risk to develop any of those complications per 1% increase in HbA1C. For the Reimbursement of orlistat in type 2 diabetes J Ruof et al purpose of our model, transitions covering a time horizon of 11 y (1 y of initial treatment and 10 y of modellingFbased on the UKPDS time frame) were designed.
The model structure simulated two courses of events (the two branches of the model; see Figure 1 ) among obese type 2 diabetic individuals. In one course, patients received standard treatment with drugs (sulfonylurea, metformin or insulin) and a weight program (caloriereduced diet and exercise) in accordance with the current standards for medical care of diabetes patients. 8 The other course described patients who received orlistat 120 mg three times daily in addition to standard antidiabetic drugs and a weight program. The baseline health status of all obese diabetics was normal, with no diabetes-related complications. Each subsequent year, patients could remain free of complications or develop one of several diabetes-related micro-or macrovascular conditions, from which they either recovered or died. Over the course of the model, patients grew older and the risk of complications increased. The incidence of secondary diseases per year was linked to HbA1C values in responders and nonresponders. In accordance with the National Institute of Clinical Excellence in the United Kingdom (http:// www.nice.org.uk), the present authors assumed that the treatment-related effect on HbA1C was lost in the 3 y following completion of the trial (base-case analysis). For the purposes of the sensitivity analysis, the period was reduced to only 2 y. Changes in HbA1C were modelled over time and translated into diabetes-related end points using the risk equations developed in the UKPDS study (Table 1a) . Based on the change in HbA1C, the respective 'Markov Subtrees' model the risk of developing any of the diabetes-related complications for each of the four branches displayed in Figure 1 . Utilities represent an attempt to quantify the dimensions of health from a patient's perspective into a generic *Responder defined as patient who achieved >5% weight loss from baseline at week 12 § The Markov subtree included all the complications specified in Where several values were reported, the higher (more conservative) values were used. Costs of complications in Switzerland and Sweden were calculated using public sources. The drug costs for metformin (Glucophage, per g), orlistat (Xenical, 120 mg), sulfonylurea (Euglucon, per g) and insulin (Insulatard, per unit) were entered in the model ( Table 2) .
The model was developed using Microsoft Excel. The pooled analysis was carried out using SAS.
Results

Meta-analysis
A total of 1249 patients treated with orlistat and 1230 treated with placebo were eligible for the ITT analysis. Baseline characteristics of the study population were as shown in Table 3 . The distribution of risk factors at baseline between the two study groups was homogeneous: 32.9% of placebo controls and 33.8% of orlistat patients had an LDL/HDL ratio Z3.5; 63.7 and 65.4%, respectively, had an SBP of Z130 mmHg; and 63.4 and 65.4% had a DBP of Z80 mmHg. Table 4 illustrates the clinical outcome of the pooled analysis. After 12 weeks, 23% of patients in the orlistat group achieved a weight loss of Z5%, and 49% achieved a loss of Z3%. At the same time point, 59% exhibited a Z0.6% reduction in HbA1C. Patients who achieved a weight reduction of Z3% showed a decrease in HbA1C of 0.96% at study end; those whose HbA1C dropped by Z0.6% at week 12 achieved a reduction in HbA1C of 1.1% at study end.
Cost-effectiveness analysis
The results of the base-case analyses for both Switzerland and Sweden were very similar, as shown in Table 5 . Costs per Reimbursement of orlistat in type 2 diabetes J Ruof et al quality-adjusted life year (QALY) gained were h14 000 in Sweden and h13 600 in Switzerland. Table 5 also shows the sensitivity analyses. Overall, the base-case figures proved to be very robust, with a maximum of h20 700 (Sweden) and h21 300 (Switzerland) per QALY when the HbA1C effect was assumed to persist for 2 y instead of 3 y. Use of upper range cost assumptions reduced the costs per QALY to h7900 in Sweden and h7500 in Switzerland.
It was possible to decrease doses or discontinue at least one antidiabetic medication in 24.3% of orlistat-treated patients vs 17.5% of placebo controls (Po0.0001). However, the impact on the observed cost-effectiveness ratios was minimal due to the generally low price of the most commonly used generic antidiabetic agents.
Health authority responses
The Swiss authorities decided to reimburse orlistat in the treatment of diabetic patients with BMI Z28 kg/m 2 , but stipulated that it should be continued beyond 6 months only in patients who lose Z5 kg of their initial body weight or achieve a reduction in HbA1C of Z0.5% (http://www.bsv. admin.ch). In Sweden, reimbursement (http://www.lfn.se) also covers diabetic patients with BMI Z28 kg/m 2 ; however, treatment with orlistat may be initiated only if diet alone has already resulted in a weight reduction of at least 2.5 kg over 4 consecutive weeks. Furthermore, treatment should be continued beyond 3 months only if patients lose an additional Z5% of their body weight.
Due to the lack of a lead-in period in the diabetes trials, the present authors were unable to assess the clinical outcomes of implementing the Swedish criteria. However, clinical outcomes associated with the two reimbursement criteria set by the Swiss authorities (Z5 kg weight loss or Z0.5% loss in HbA1C after 6 months) were as shown in Table 6 .
Discussion
The results of this analysis underline the favorable clinical outcomes and the cost-effectiveness of orlistat in patients with type 2 diabetes who show a reduction in weight in accordance with the European label (ie Z5% after 3 months). Responding patients show significant reductions in all relevant metabolic risk parameters: weight 8.6 kg; waist circumference 8.2 cm; HbA1C 1.16%; total cholesterol 5.3%; LDL-cholesterol 3.9%; and systolic blood pressure 5.2 mmHg. The metabolic effects translate into beneficial cost-effectiveness: h14 000 and h13 600 per QALY gained in Sweden and Switzerland, respectively. The present approach is very similar to that adopted in other health economic analyses of orlistat in obese and overweight patients with type 2 diabetes. 22, 23 Lamotte et al 22 reported figures per 'Life Year Gained' of h19 986 in obese diabetic patients (base-case) and h3462 in obese diabetic patients with hypertension and hypercholesterolemia. As the present model relied on HbA1C and weight as risk factors and did not factor in other metabolic parameters (LDLcholesterol, total cholesterol, blood pressure), it was not possible to conduct a sensitivity analysis in patients with a cluster of risk factors (ie diabetes, hypercholesterolemia and hypertension). However, the base-case analyses showed The approach presented in this paper was included in dossiers submitted to reimbursement authorities in Sweden and Switzerland. For the purposes of the current publication, the model was rerun for both countries with homogeneous settings and minor updates (conversion rate and drug price) in order to produce data suitable for comparison. The costeffectiveness ratios presented in Table 5 are therefore slightly different from the original base-case ratios in local currencies CHF 22 061 (Switzerland) and sKr 122 381 (Sweden) per QALY. The submitted data were reviewed by independent scientific review committees assigned by those authorities, and contributed to the favorable reimbursement decision adopted. However, in both countries, the final criteria apply slightly different definitions of response to those adopted here. Sweden requires a weight loss of 2.5 kg prior to initiating orlistat, and a loss of at least 5% after 12 weeks of treatment (www.lfn.se). The Swiss recommendations require a weight loss of Z5 kg or a reduction in HbA1C of Z0.5% after 6 months of treatment (www.bsv.admin.ch). Debate about the various definitions of response has raised the following arguments:
In 2003, Rissanen et al 24 suggested that weight loss of Z5% accurately predicts sustained improvements in weight and major risk factors, whereas the addition of any lead-in criteria (ie weight loss prior to starting treatment) is less useful. Although the data predate the Rissanen publication, the pooled analysis focused only on patients who achieved a weight loss of Z5% after 12 weeks, and took no account of lead-in requirements. It is well known that weight loss is more difficult to achieve in diabetic than nondiabetic patients. 25, 26 It can therefore be argued that the addition of HbA1C as a response parameter (as in Switzerland) or a weight loss of less than the Z5% (for example, Z3%) specified for the general obese population in the European label would better define response in obese and overweight type 2 diabetics. The assumptions were tested in a sensitivity analysis. The results, however, indicate that variation in the chosen response criteria (Z3% weight loss after 12 weeks and Z0.6% reduction in HbA1C) had only a limited impact on both clinical outcome and cost-effectiveness (see Table 4 ). This is due to the conservative general structure of the model, in which the medical outcome in nonresponding orlistat patients (in whom treatment should, according to the algorithm, be terminated after 12 weeks) was considered similar to the outcome in nonresponding placebo controls.
The present authors take the view that, whatever the detailed definition of response used, targeting of subpopulations that really benefit from weight-loss treatments is a core element of any strategy intended to address the dramatically evolving epidemic of obesity. This approach has been adopted in the guidance on orlistat provided by the National Institute of Clinical Excellence in the United Kingdom (http://www.nice.org.uk) and was also applied by the two countries included in the current review. The selection of a subset of patients who show a benefit from weight loss treatments is critical.
In conclusion, the data presented here support the utilization and reimbursement of orlistat in overweight and obese diabetic patients who respond to the treatment. 
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